DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A (BoNTA) product that contains a highly purified 150-kDa core neurotoxin and a proprietary stabilizing excipient peptide (RTP004) instead of human serum albumin. DAXI produces robust and extended efficacy in reducing glabellar lines and improving Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores in adults with cervical dystonia. DAXI has a consistent median time to loss of none or mild glabellar line severity of 24 weeks and a median time until return to baseline of up to 28 weeks. Overall, DAXI is well-tolerated and has the potential to improve the management of both aesthetic and therapeutic conditions due to its consistent and extended duration of effect. The US FDA approved the development of daxibotulinumtoxinA (DAXI) for injection on September 16, 2022, based on positive results from clinical trials (SAKURA 1, 2, and 3). DAXI’s extended duration of effect could make it a reliable and safe option for reducing the appearance of wrinkles caused by muscle activity, and it has the potential to improve the treatment of both therapeutic and cosmetic disorders.

Keywords: Glabellar lines, Botulinum neurotoxin, DaxibotulinumtoxinA, SAKURA, Wrinkles